Skip to main content
BrainCited

The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment.

B L Jorissen, F Brouns, M P Van Boxtel, R W Ponds, F R Verhey et al.
CCT Nutritional neuroscience 2001 66 Zitierungen
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'pmid\u003D11842880'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Studientyp
Randomized Controlled Trial
Population
Aging subjects with memory complaints
Dauer
12 weeks
Intervention
The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Soy-derived phosphatidylserine (S-PS)
Vergleichsgruppe
Placebo
Primärer Endpunkt
Cognitive function (memory, learning)
Wirkungsrichtung
Positive
Verzerrungsrisiko
Low

Abstract

Phosphatidylserine (PS) is a phospholipid widely sold as a nutritional supplement. PS has been claimed to enhance neuronal membrane function and hence cognitive function, especially in the elderly. We report the results of a clinical trial of soybean-derived PS (S-PS) in aging subjects with memory complaints. Subjects were 120 elderly (> 57 years) of both sexes who fulfilled the more stringent criteria for age-associated memory impairment (AAMI); some also fulfilled the criteria for age-associated cognitive decline. Subjects were allocated at random to one of the three treatment groups: placebo, 300mg S-PS daily, or 600mg S-PS daily. Assessments were carried out at baseline, after 6 and 12 weeks of treatment, and after a wash-out period of 3 weeks. Tests of learning and memory, choice reaction time, planning and attentional functions were administered at each assessment. Delayed recall and recognition of a previously learned word list comprised the primary outcome measures. No significant differences were found in any of the outcome variables between the treatment groups. There were also no significant interactions between treatment and 'severity of memory complaints'. In conclusion, a daily supplement of S-PS does not affect memory or other cognitive functions in older individuals with memory complaints.

Zusammenfassung

A daily supplement of S-PS does not affect memory or other cognitive functions in older individuals with memory complaints, and there were no significant interactions between treatment and ‘severity of memory complaints’.

Used In Evidence Reviews

Similar Papers